Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing- remitting multiple sclerosis

Frauke Zipp, Michael Weller, Peter A. Calabresi, Joseph A. Frank, Craig N. Bash, Johannes Dichgans, Henry F. McFarland, Roland Martin

Research output: Contribution to journalArticlepeer-review

Abstract

CD95/CD95 ligand interactions are critically involved in the negative regulation of peripheral T-cell responses. Here, we report that serum levels of soluble CD95 are significantly elevated in patients with relapsing remitting multiple sclerosis. In a transectional study, CD95 levels did not correlate with clinical disability or lesion formation on magnetic resonance imaging. Longitudinally, Expanded Disability Status Scale changes were associated with high CD95 levels. Interferon-β (IFNβ) treatment led to an initial increase and subsequent decline of serum CD95 levels. Interestingly, patients generating neutralizing antibodies to the drug had significantly higher baseline CD95 levels before IFNβ treatment than those without neutralizing antibodies.

Original languageEnglish (US)
Pages (from-to)116-120
Number of pages5
JournalAnnals of neurology
Volume43
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing- remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this